| Description | DescriptionTyrosyl-DNA phosphodiesterase-2 (TDP2) functions to remove trapped topoisomerase II/DNA complexes by processing 5′- blocking protein (topo II) at the site of the DNA break (Fig 1). In terms of physiological relevance, there appear to be multiple roles for TDP2, well beyond the DescriptionTyrosyl-DNA phosphodiesterase-2 (TDP2) functions to remove trapped topoisomerase II/DNA complexes by processing 5′- blocking protein (topo II) at the site of the DNA break (Fig 1). In terms of physiological relevance, there appear to be multiple roles for TDP2, well beyond the repair of type II topoisomerase damage and subsequent DNA repair. This is quite different from the Top1/DNA repair protein, TDP1. There are a number of mechanistic differences between TDP1 and 2 as well (see reviews from Pommier, PMID 24856239 and https://www.uniprot.org/uniprot/O95551). In humans, TDP2 should be considered a multi-functional enzyme with roles in TNF and MAPK/JNK/p38 pathways. There is some similarity with APE1 and the superfamily of Mg++/Mn++ dependent phosphodiesterases and there is evidence that picorna viruses pirate TDP2 as a VPg un-linkase function. Given the key role for topo II in anticancer therapy, drugs that inhibit TDP2 might prove useful in combination therapy with established Interfacial Poisons (IFP) such as doxorubicin and etoposide (VP16). Indeed, when the Tdp2 gene is suppressed, cells show enhanced sensitivity to Top2 drugs, making Tdp2 an important anti-cancer target. Shipping&storageHuman TDP-2 is shipped on wet ice and should be stored at -20°C... Read More | Dezamizumab (anti-Serum Amyloid P) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab (anti-Serum Amyloid P) triggers immunotherapeutic clearance of amyloid. Dezamizumab (anti-Serum Amyloid P) can be used Dezamizumab (anti-Serum Amyloid P) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab (anti-Serum Amyloid P) triggers immunotherapeutic clearance of amyloid. Dezamizumab (anti-Serum Amyloid P) can be used in research of Amyloid light-chain (AL) amyloidosis... Read More | Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) TFA is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) TFA is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA produces a relapsing-remitting neurological disease with extensive plaque-like demyelination... Read More | Inquire | Purity>97% by SDS-PAGE and HPLC analyses.Additional sequence informationN-terminal Glycine.FunctionChemotactic for monocytes and T-lymphocytes. Binds to CXCR3.Post-translationalCXCL10(1-73) is produced by proteolytic cleavage after secretion from keratinocytes |